RespireRx Pharmaceuticals Inc (RSPI)

[in2it]

UBS BVF analyst take on "deal"

[Thoughts on the deal: Very early stage project
Although this deal adds another opportunity in a niche indication for a modest upfront payment, we think this is a high risk deal for Biovail. Cortex tried developing CX717 for other indications (e.g., ADHD and Alzheimer’s disease) with limited success and now believes that it may work in respiratory depression.

It is too early for us to get excited about this drug. The IV formulation has not yet been developed and we will need to see some proof-of-concept data with the IV formulation before we can give some credit to this drug.]